Abstract 1245P
Background
Specific requirements of the minimum number of harvested lymph nodes for accurate nodal staging in small intestinal tumors are sparse as there is a probability that false-negative lymph nodes remain. The aim of this study is to establish a histologic-type-specific nodal staging score (NSS) model for the specific requirements of lymph nodes in small intestinal tumors by taking potential false-negative lymph nodes into consideration.
Methods
Small intestinal tumors with complete follow-up and examined/positive lymph nodes data were retrieved using the Surveillance, Epidemiology, and End Results program. Using a beta-binomial model, the probability of lymph nodes with occult disease and the NSS model were established.
Results
A total of 7649 small intestinal tumors were retrieved, including 3789 carcinoid cases, 2467 adenocarcinoma cases, 718 neuroendocrine carcinoma cases, 502 sarcoma cases, and 173 others. To reach a 0.05 false-negative probability, the minimum number of lymph nodes was 10 in carcinoid tumors, 11 in adenocarcinoma, 12 in neuroendocrine carcinoma, 7 in sarcoma, and 16 in others. Distinct NSS curves were presented among each histologic type of small intestinal tumors. The NSS of neuroendocrine carcinoma indicated that a higher number of lymph nodes was required to enable the correct staging of lymph nodes compared to other types of small intestinal tumors. The prognostic values of NSS quartiles were validated.
Conclusions
The minimum required number of examined lymph nodes varied in each histologic type of small intestinal tumors. The NSS improved the adequacy of nodal staging for patients for clinical interpretation and decision making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1251P - Development of a deep learning algorithm for lung cancer diagnosis using methylation and fragment size profiles of cfDNA
Presenter: Jiyoung Huh
Session: Poster session 14
1252P - Quantitative cell signaling activity profiling of solid tumors to support personalized treatment in the FINPROVE basket trial: Presentation of skin tumor data
Presenter: Diederick Keizer
Session: Poster session 14
1253P - Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD)
Presenter: Marcel Trautmann
Session: Poster session 14
1254P - Retrospective analysis of brain OMX: Diagnostic tool for structural (T1) and functional connectome (RS-FMRI) analysis of brain
Presenter: Swarnambiga Ayyachamy
Session: Poster session 14
1255P - Evaluating GPT-4 as an academic support tool for clinicians: A comparative analysis of case records from the literature
Presenter: Marcos Aurelio Fonseca Magalhaes Filho
Session: Poster session 14
1256P - Value of detection of peripheral blood circRNA based on digital PCR in the diagnosis of lung adenocarcinoma
Presenter: Jihong Zhou
Session: Poster session 14
1257P - Double heterozygous prevalence in hereditary cancer syndromes in Northern Mexico population
Presenter: Carlos Burciaga Flores
Session: Poster session 14
1258P - Does FDG PET-based radiomics have an added value for prediction of overall survival in non-small cell lung cancer?
Presenter: Andrea Ciarmiello
Session: Poster session 14
1260TiP - Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach
Presenter: Young-Chul Kim
Session: Poster session 14
1773P - ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era
Presenter: Wanling Xie
Session: Poster session 14